分子组织学与医学生理学杂志

The microbiome of the human gastrointestinal tract is a very complex and dynamic internal prokaryotic ecology with incredible variety, diversification, and complexity. This dynamic repository of microorganisms has the world's biggest interactive source and greatest density of bacteria, together forming the world's largest 'diffuse organ system' that is at least as metabolically active as the liver. This microbiome has a significant impact on the health, wellbeing, and vitality of the human host via the extracellular fluid (ECF), cerebrospinal fluid (CSF), lymphatic and glymphatic circulation, endocrine, systemic, and neurovascular circulation, and/or the central and peripheral nervous systems (CNS, PNS). The Human Microbiome Initiative (HMI) and the Unified Human Gastrointestinal Genome (UHGG) consortium recently classified over 200 thousand diverse, non-redundant prokaryotic genomes in the human GI-tract microbiome, involving approximately 5,000 different GI-tract microbes that encode nearly 200 million different protein sequences.

Every year, roughly 40,000 Americans and 350,000 people worldwide are diagnosed with oral cancer for the first time. In the general population, oral cancer is the sixth most frequent disease for both men and women, and the third most common cancer in developing countries. About half of those affected will die within five years of being diagnosed, while those who survive will likely have significant cosmetic and/or functional problems. Oral cancer is defined as cancer of the oral cavity and pharynx, which includes cancers of the lip, tongue, salivary glands, gum, floor, and other regions of the mouth, oropharynx, nasopharynx, hypopharynx, pharynx, and other buccal areas, according to the International Classification of Diseases. Carcinomas account for 96 percent of all oral malignancies, with squamous cell carcinomas accounting for 91 percent.

Bladder dangerous development is a heterogeneous disease, with 70% of patients giving shallow tumors, which will in everyday rehash however are all around not unsafe, and 30% presenting as a muscle-prominent disorder related with a high risk of death from distant metastases. The central presenting sign of all bladder malignancies is simple haematuria, furthermore, the finding is set up by urinary cytology and transurethral tumor resection. Intravesical treatment is used for carcinoma in situ and other highgrade non-muscle-prominent tumors. The standard of care for the muscle-meddling sickness is progressive development prostatectomy, and a couple of kinds of urinary redirections are offered to patients, with individual fulfilment as a critical idea. Bladder defending with transurethral tumor resection, radiation, and chemotherapy can now and then be also corrective.

We are glad to share that with the tremendous efforts of our journal team as well as continuous support of the editors and contributions of reviewers and authors, we are able to release regular monthly issues on the journal website. Not only we are confined to digital issue release but also, we have provided numerous reprints (hardcopy/printed copy of the manuscript) of the particular articles/issues/volumes to the authors as per their requirement. Woefully, due to the pandemic situation and consequently lockdown, we were unable to provide reprints to the authors as the transportation facility was restricted. Now, it is of immense pleasure to know that everything is going to be resuming and reschedule like before and we can continue our services without any further barriers

It is of immense delectation to share with our readers/authors/editors/reviewers that Journal of Molecular Histology and Medical Physiology had successfully disseminated 5 Volumes worldwide through the journal platform. Currently, we are on the way to promulgate more updates in the field of Molecular Histology and Medical Physiology. We would like to acknowledge the contributors of our journal for their time-honoured support and cooperation in bringing and publishing the issues on journal website within time. With reference to the previous submissions received in the journal, we request the eminent authors to come up with their valuable submissions based on their recent on-going studies related to the molecular biology, molecular histology, medical physiology, cancer cells, physiology and other such topics that cover the journal scope.